TWI445539B - 特定化合物、組合物及方法 - Google Patents

特定化合物、組合物及方法 Download PDF

Info

Publication number
TWI445539B
TWI445539B TW097139594A TW97139594A TWI445539B TW I445539 B TWI445539 B TW I445539B TW 097139594 A TW097139594 A TW 097139594A TW 97139594 A TW97139594 A TW 97139594A TW I445539 B TWI445539 B TW I445539B
Authority
TW
Taiwan
Prior art keywords
compound
cancer
cda
group
formula
Prior art date
Application number
TW097139594A
Other languages
English (en)
Chinese (zh)
Other versions
TW200924786A (en
Inventor
Gregory S Hamilton
Takashi Tsukamoto
Dana V Ferraris
Bridget Duvall
Rena Lapidus
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40251685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI445539(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of TW200924786A publication Critical patent/TW200924786A/zh
Application granted granted Critical
Publication of TWI445539B publication Critical patent/TWI445539B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW097139594A 2007-10-16 2008-10-15 特定化合物、組合物及方法 TWI445539B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98039707P 2007-10-16 2007-10-16

Publications (2)

Publication Number Publication Date
TW200924786A TW200924786A (en) 2009-06-16
TWI445539B true TWI445539B (zh) 2014-07-21

Family

ID=40251685

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097139594A TWI445539B (zh) 2007-10-16 2008-10-15 特定化合物、組合物及方法

Country Status (39)

Country Link
US (4) US8268800B2 (enExample)
EP (2) EP2447272B1 (enExample)
JP (2) JP5496899B2 (enExample)
KR (1) KR101543049B1 (enExample)
CN (1) CN101827856B (enExample)
AT (1) ATE548374T1 (enExample)
BR (1) BRPI0818672B8 (enExample)
CA (1) CA2702274C (enExample)
CO (1) CO6270330A2 (enExample)
CR (1) CR11427A (enExample)
CY (3) CY1112781T1 (enExample)
DK (1) DK2207786T3 (enExample)
EA (1) EA018757B1 (enExample)
EC (1) ECSP10010095A (enExample)
ES (2) ES2616566T3 (enExample)
FI (2) FIC20230040I1 (enExample)
FR (2) FR23C1052I2 (enExample)
GT (1) GT201000088A (enExample)
HR (1) HRP20120419T1 (enExample)
HU (2) HUS2300044I1 (enExample)
IL (1) IL204732A (enExample)
JO (1) JO2778B1 (enExample)
LT (2) LTPA2023539I1 (enExample)
ME (1) ME00997B (enExample)
MX (1) MX2010004109A (enExample)
MY (1) MY147970A (enExample)
NI (1) NI201000055A (enExample)
NL (2) NL301256I2 (enExample)
NO (2) NO2023047I1 (enExample)
NZ (1) NZ584229A (enExample)
PL (1) PL2207786T3 (enExample)
PT (1) PT2207786E (enExample)
RS (1) RS52323B (enExample)
SA (1) SA08290661B1 (enExample)
SI (1) SI2207786T1 (enExample)
TW (1) TWI445539B (enExample)
UA (1) UA99476C2 (enExample)
WO (1) WO2009052287A1 (enExample)
ZA (1) ZA201002178B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
US8846628B2 (en) 2008-05-15 2014-09-30 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20100055047A1 (en) * 2008-08-26 2010-03-04 Yiyu Zou Methods for treating bronchial premalignancy and lung cancer
NZ593647A (en) 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
JP5684787B2 (ja) * 2009-04-06 2015-03-18 大塚製薬株式会社 シチジンベースの抗新生物薬とシチジンデアミナーゼ阻害薬との組合せ、および癌の治療におけるその使用
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
JO3262B1 (ar) * 2009-04-06 2018-09-16 Otsuka Pharma Co Ltd توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان
AR076262A1 (es) * 2009-04-06 2011-06-01 Eisai Inc Derivados heterociclicos de diazepin-2-ona, composiciones farmaceuticas y sus usos en el tratamiento del cancer
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
CA2840242C (en) 2011-09-16 2019-03-26 Gilead Sciences, Inc. Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
KR20200060782A (ko) 2013-01-31 2020-06-01 길리애드 파마셋 엘엘씨 두 항바이러스 화합물의 병용 제형물
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
ES2712877T3 (es) 2013-10-29 2019-05-16 Otsuka Pharma Co Ltd Ruta sintética de 2’-desoxi-2’,2’-difluorotetrahidrouridinas
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
LT3182996T (lt) 2014-08-22 2023-03-10 Celgene Corporation Daugybinės mielomos gydymo būdai imunomoduliuojančiais junginiais derinyje su antikūnais
CA3007357C (en) * 2015-12-03 2023-12-05 Epidestiny, Inc. Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
AU2019216531A1 (en) 2018-02-02 2020-09-24 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
JP2021535395A (ja) * 2018-08-28 2021-12-16 エッセンリックス コーポレーション アッセイ精度向上
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
CN112888700B (zh) * 2018-10-19 2025-03-04 因特欧力多公司 具有改善治疗功效的修饰核酸和含有其的抗癌药物组合物
JP7433662B2 (ja) 2018-10-19 2024-02-20 インターオリゴ・コーポレイション 治療効能を改善した核酸変形体及びそれを含む抗癌用薬学組成物
US12187757B2 (en) * 2019-10-08 2025-01-07 Otsuka Pharmaceutical Co., Ltd. 2′-deoxy-2′,2′-difluorotetrahydrouridines with high purity and methods of making the same
IL294288A (en) * 2020-02-25 2022-08-01 Otsuka Pharma Co Ltd Solid oral dosage forms in combination with decitabine and cadazuridine
AU2022244240A1 (en) * 2021-03-26 2023-10-05 The Cleveland Clinic Foundation Treatment of rna virus infection with a cytidine deaminase inhibitor
US20240279266A1 (en) * 2021-05-29 2024-08-22 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
AU2022370354A1 (en) 2021-10-19 2024-05-30 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
WO2023076332A1 (en) * 2021-11-01 2023-05-04 St. John's University Injectable liquid pharmaceutical compostion containing gemcitabine and a cytidine deaminase inhibitor
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine
WO2024047394A1 (en) 2022-08-31 2024-03-07 Otsuka Pharmaceutical Co., Ltd. Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
US4275057A (en) 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
WO1985001871A1 (en) 1983-10-26 1985-05-09 Greer Sheldon B Method and materials for sensitizing neoplastic tissue to radiation
DE3587500T2 (de) 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
WO1992018617A1 (en) 1991-04-23 1992-10-29 Oglevee, Ltd. In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr) 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5594124A (en) 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5371210A (en) 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5606048A (en) 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
DE69403588T2 (de) 1993-02-23 1998-01-22 Hope City 4-ethoxy-5-fluor-2'-deoxyuridine
AU6081294A (en) 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
WO1996026743A1 (en) * 1995-03-01 1996-09-06 Human Gene Therapy Research Institute Radiation enhanced gene therapy for treatment of tumors
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
US6933287B1 (en) 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
DK1156827T3 (da) * 1999-03-01 2007-02-05 Halogenetics Inc Anvendelse af sammensætninger omfattende CldC som strålingssensibilisatorer ved behandlingen af neoplastiske sygdomme
EP1207783A1 (en) 1999-08-26 2002-05-29 Aortech International PLC Improvements relating to catheter positioning
US6462191B1 (en) 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
EP1348712B1 (en) 2000-11-29 2011-05-04 Mitsui Chemicals, Inc. Processes and intermediates in the synthesis of L-thymidine
WO2002056912A2 (en) 2001-01-16 2002-07-25 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
US7589077B2 (en) 2001-05-18 2009-09-15 Rakesh Kumar Antiviral nucleosides
EP1418949B1 (en) * 2001-07-31 2013-06-19 THE STATE OF OREGON acting by and through THE STATE BOARD OF HIGHER EDUCATION on behalf of THE UNIVERSITY OF OREGON Inhibitor of dna methylation
US20040002476A1 (en) 2002-02-14 2004-01-01 Stuyver Lieven J. Modified fluorinated nucleoside analogues
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
EP1545558A4 (en) 2002-09-24 2010-02-17 Koronis Pharmaceuticals Inc 1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES
WO2004041203A2 (en) 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US8158770B2 (en) 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
WO2006015346A1 (en) 2004-07-30 2006-02-09 Pharmaessentia Corp. STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
JP2007522151A (ja) 2004-12-08 2007-08-09 シコール インコーポレイティド ジフルオロヌクレオシド及びその調製方法
WO2008085611A2 (en) * 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
AR076262A1 (es) 2009-04-06 2011-06-01 Eisai Inc Derivados heterociclicos de diazepin-2-ona, composiciones farmaceuticas y sus usos en el tratamiento del cancer
JO3262B1 (ar) 2009-04-06 2018-09-16 Otsuka Pharma Co Ltd توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان
JP5684787B2 (ja) 2009-04-06 2015-03-18 大塚製薬株式会社 シチジンベースの抗新生物薬とシチジンデアミナーゼ阻害薬との組合せ、および癌の治療におけるその使用
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer

Also Published As

Publication number Publication date
EP2207786B1 (en) 2012-03-07
US20150210730A1 (en) 2015-07-30
ECSP10010095A (es) 2010-07-30
EA201000642A1 (ru) 2010-10-29
CA2702274A1 (en) 2009-04-23
NO2023047I1 (no) 2023-12-21
ES2384011T3 (es) 2012-06-28
IL204732A0 (en) 2010-11-30
HK1146410A1 (en) 2011-06-03
NZ584229A (en) 2012-06-29
LTPA2023539I1 (enExample) 2024-02-26
EP2207786A1 (en) 2010-07-21
AU2008312435B2 (en) 2014-04-17
NI201000055A (es) 2010-08-13
US20090137521A1 (en) 2009-05-28
BRPI0818672B8 (pt) 2021-05-25
UA99476C2 (en) 2012-08-27
MY147970A (en) 2013-02-28
FR23C1051I1 (fr) 2024-01-26
FR23C1052I1 (fr) 2024-01-26
PL2207786T3 (pl) 2012-09-28
ES2616566T3 (es) 2017-06-13
CN101827856B (zh) 2013-02-06
US9567363B2 (en) 2017-02-14
IL204732A (en) 2013-07-31
NL301256I2 (nl) 2024-01-11
MX2010004109A (es) 2010-08-10
CY2023028I1 (el) 2024-02-16
JP5859588B2 (ja) 2016-02-10
HUS2300044I1 (hu) 2024-01-28
KR101543049B1 (ko) 2015-08-07
SA08290661B1 (ar) 2012-06-10
AU2008312435A1 (en) 2009-04-23
BRPI0818672B1 (pt) 2020-10-20
NO2023048I1 (en) 2023-12-21
EP2447272B1 (en) 2017-02-01
EA018757B1 (ru) 2013-10-30
SI2207786T1 (sl) 2012-10-30
ATE548374T1 (de) 2012-03-15
ZA201002178B (en) 2011-05-25
US20120289475A1 (en) 2012-11-15
JO2778B1 (en) 2014-03-15
JP5496899B2 (ja) 2014-05-21
CY2023029I1 (el) 2024-02-16
RS52323B (sr) 2012-12-31
TW200924786A (en) 2009-06-16
CA2702274C (en) 2015-12-29
DK2207786T3 (da) 2012-06-18
US8618075B2 (en) 2013-12-31
US8268800B2 (en) 2012-09-18
JP2011500713A (ja) 2011-01-06
BRPI0818672A2 (pt) 2015-04-14
US20140186335A1 (en) 2014-07-03
NL301256I1 (enExample) 2024-01-03
FR23C1052I2 (fr) 2025-02-07
FIC20230040I1 (fi) 2023-12-22
JP2014177455A (ja) 2014-09-25
FIC20230039I1 (fi) 2023-12-22
EP2447272A1 (en) 2012-05-02
ME00997B (me) 2012-10-20
WO2009052287A1 (en) 2009-04-23
CN101827856A (zh) 2010-09-08
CY1112781T1 (el) 2016-02-10
NL301257I2 (nl) 2025-11-06
US8951987B2 (en) 2015-02-10
AU2008312435A8 (en) 2014-07-24
LTC2207786I2 (enExample) 2025-09-10
FR23C1051I2 (fr) 2025-02-07
GT201000088A (es) 2012-03-13
HUS2300045I1 (hu) 2024-01-28
CO6270330A2 (es) 2011-04-20
LTPA2023538I1 (enExample) 2024-02-26
HRP20120419T1 (hr) 2012-07-31
KR20100091978A (ko) 2010-08-19
PT2207786E (pt) 2012-05-28
CR11427A (es) 2010-08-16

Similar Documents

Publication Publication Date Title
TWI445539B (zh) 特定化合物、組合物及方法
TW200927105A (en) Process for the preparation of compounds useful as inhibitors of SGLT
TWI503121B (zh) 用以治療癌症之組成物及方法
NO175620B (enExample)
WO2016155593A1 (zh) 4'-硫代核苷的新型化合物及其制备方法、药物组合物和应用
CN103619840A (zh) (s)-吡咯烷-1,2-二羧酸2-酰胺1-({4-甲基-5-[2-(2,2,2-三氟-1,1-二甲基-乙基)-吡啶-4-基]噻唑-2-基}酰胺的多晶型物
TWI477508B (zh) 用以治療癌症之組成物及方法
EP4259148A1 (en) Phosphonates as inhibitors of enpp1 and cdnp
TWI449528B (zh) ３’-乙炔基胞嘧啶核苷衍生物
AU2008312435B8 (en) 2 ' -fluoro-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors
JPH0413328B2 (enExample)